The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALX ONCOLOGY HLDGS INC | COM | 00166B105 | 43,843,661 | 9,699,925 | SH | SOLE | 9,699,925 | 0 | 0 | ||
ELEVATION ONCOLOGY INC | COM | 28623U101 | 3,546,044 | 1,866,339 | SH | SOLE | 1,866,339 | 0 | 0 | ||
HARMONY BIOSCIENCES HLDGS IN | COM | 413197104 | 33,805,679 | 1,035,396 | SH | SOLE | 1,035,396 | 0 | 0 | ||
IMPEL PHARMACEUTICALS INC | COM | 45258K109 | 3,863,707 | 2,759,791 | SH | SOLE | 2,759,791 | 0 | 0 | ||
PHARVARIS N V | COM | N69605108 | 18,353,922 | 2,278,575 | SH | SOLE | 2,278,575 | 0 | 0 | ||
VENTYX BIOSCIENCES INC | COM | 92332V107 | 77,010,906 | 2,298,833 | SH | SOLE | 2,298,833 | 0 | 0 |